| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Voyager Therapeutics (NASDAQ:VYGR) with a Buy and lowers the p...
-SEC Filing
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...
Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining ...
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $...
Wedbush analyst Yun Zhong maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and lowers the price target from $9...
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate o...